report details:
Published March 2005
172 pages
30 tables
Price: $3950.00
summary
The total worldwide market for therapeutic vaccines was $8.1 million in 2004. With increased product introductions, this market is expected to top $4 billion in 2010. The report contains:
An emphasis on companies poised to introduce products during the forecast period
Analysis of how these introductions will play out in terms of the competitive environment
Focus on how new products and technologies are likely to define market leaders in the therapeutic vaccine arena
Forecasts by product segment and indication through 2010, including supporting analyses
Profiles of companies projected to have therapeutic vaccine products on the market during the period.
table of contents
INTRODUCTION
XIV
STUDY GOAL AND OBJECTIVES
XIV
REASONS FOR DOING THE STUDY
XIV
CONTRIBUTIONS OF THE STUDY AND FOR WHOM
XIV
SCOPE AND FORMAT
XIV
METHODOLOGY
XV
INFORMATION SOURCES
XV
RELATED BCC WORK CREDENTIALS INCLUDING WORK DONE BY OTHER AUTHORS
XV
BCC ON-LINE SERVICES
XVI
DISCLAIMER
XVI
EXECUTIVE SUMMARY
XVII
Summary Table:
THE WORLDWIDE MARKET FOR THERAPEUTIC VACCINES BY INDICATION, THROUGH 2010 ($ MILLIONS)
XVIII
Summary Figure:
THE WORLDWIDE MARKET FOR THERAPEUTIC VACCINES BY INDICATION, 2003-2010
XVIII
OVERVIEW
1
DEFINITION OF A THERAPEUTIC VACCINE
1
IMMUNE SYSTEM OVERVIEW: CAST OF CHARACTERS
1
B-CELLS, T-CELLS AND ANTIGEN-PRESENTING CELLS
1
B-Cells
1
T-Cells
2
Antigen-Presenting Cells
2
CELLULAR VS. HUMORAL IMMUNITY
2
INNOVATIVE APPROACHES TO VACCINE TECHNOLOGY
3
DNA VACCINES
3
CARBOHYDRATE VACCINES
3
Therapeutic Cancer Vaccines
4
Therapeutic AIDS Vaccines
5
ADJUVANTS
6
STATISTICAL POWER AND WHAT IT MEANS IN CLINICAL TRIALS
6
THE FDA MODERNIZATION ACT OF 1997
6
FAST TRACK STATUS
6
SPECIAL PROTOCOL ASSESSMENT
7
PRODUCTS
8
ADDICTION VACCINES
8
Table 1 THE WORLDWIDE MARKET FOR ADDICTION VACCINES BY TYPE OF ADDICTION, THROUGH 2010 ($ MILLIONS)
9
COCAINE ADDICTION VACCINES
9
The Market for Cocaine Addiction Vaccines
10
Table 2 THE WORLDWIDE MARKET FOR COCAINE ADDICTION VACCINES: THROUGH 2010 ($ MILLIONS)
10
TA-CD
10
NICOTINE ADDICTION VACCINES
11
The Market for Nicotine Addiction Vaccines
12
Table 3 THE WORLDWIDE MARKET FOR NICOTINE ADDICTION VACCINES: THROUGH 2010 ($ MILLIONS)
13
Cytos Vaccine
13
NicVAX
14
TA-NIC
15
Prommune Vaccine
16
PROPHYLACTIC ADDICTION VACCINES
16
AUTOIMMUNE DISEASE VACCINES
17
DIABETES VACCINE AND IMMUNOTHERAPY RESEARCH COORDINATING CENTRE
17
DIAMYD MEDICAL
18
STANFORD MEDICAL CENTER
19
Stanford Medical Center (Continued)
20
TECHNION-ISRAEL INSTITUTE
21
UNIVERSITY OF BRISTOL
21
CANCER VACCINES
22
CANCER STATISTICS
22
U.S. Cancer Statistics
23
Table 4 INCIDENCE, MORTALITY, AND SURVIVAL RATES FOR COMMON CANCERS IN THE U.S., 2003
24
Table 5 CANCER PREVALENCE RATES IN THE U.S., 2003
24
Table 5 (CONTINUED)
25
Table 6 ANNUAL INCIDENCE OF, AND DEATH RATES FOR CANCERS FOR WHICH THERAPEUTIC VACCINES ARE IN DEVELOPMENT IN THE U.S., 2003
25
Current Treatment Methods
26
Surgery
26
Radiation Therapy
26
Pharmaceutical Therapy
27
Prophylactic Vaccine for Hepatitis B
28
Cancers for Which Vaccines Are in Phase II or Later Development
28
Bladder Cancer
28
Breast Cancer
28
Cervical Cancer
28
Colorectal Cancer
29
Esophageal and Gastric Cancer
30
Lung Cancer
30
Melanoma
30
Multiple Myeloma
31
Myelogenous Leukemia
32
Non-Hodgkin's Lymphoma
32
Pancreatic Cancer
32
Prostate Cancer
33
Renal Cell Carcinoma
33
CANCER VACCINES: A NEW MODALITY OF CARE
34
The Primary Therapeutic Role for Cancer Vaccines
34
The Immune System and Cancer
35
Antigens: Their Role in Cancer Vaccines
36
Antigens Used in Cancer Vaccine Development
36
Carcinoembryonic Antigen
36
Ganglioside Molecules
37
Heat Shock Proteins
37
MART-1
37
Prostate-Specific Antigen
38
Sialyl Tn
38
Tyrosinase
38
Vaccine Development: Strategies
38
Vaccine Development: Strategies (Continued)
39
A Summary of Two Approaches: Low-technology vs. High-technology
40
Vaccine Types
40
Antigen/Adjuvant Vaccines
40
Dendritic Cell Vaccines (DCs)
41
DNA and Viral Vector Vaccines
41
Idiotype Vaccines
41
Oncolytic Virus Vaccines
41
Whole Cell Tumor Vaccines
42
Table 7 TYPES OF VACCINES IN DEVELOPMENT FOR CANCER TREATMENT
42
The Long Road to Market
43
The Market for Cancer Vaccines
43
Table 8 ESTIMATED U.S. MARKET FOR CANCER VACCINES BY INDICATION
44
Table 9 WORLDWIDE MARKET FOR CANCER VACCINES BY TYPE, THROUGH 2010 ($ MILLIONS)
44
Table 9 (CONTINUED)
45
Table 10 THE MARKET FOR CANCER VACCINES, BY TECHNOLOGY (AUTOLOGOUS VERSUS ALLOGENEIC), WORLDWIDE, THROUGH 2010 ($ MILLIONS)
45
Figure 1 PERCENTAGE OF THE MARKET HELD BY AUTOLOGOUS VERSUS ALLOGENEIC CANCER VACCINES, WORLDWIDE, 2005 AND 2010 (%)
46
Table 11 THE WORLDWIDE MARKET FOR CANCER VACCINES, BY INDICATION, THROUGH 2010 ($ MILLIONS)
46
Figure 2 THERAPEUTIC CANCER VACCINE MARKET SHARE BY COMPANY, 2004 AND 2010 (%)
47
CANCER VACCINES IN DEVELOPMENT
48
Table 12 CANCER VACCINES IN PHASE II OR LATER TRIALS
48
Table 12 (CONTINUED)
49
Table 12 (CONTINUED)
50
Table 12 (CONTINUED)
51
Table 12 (CONTINUED)
52
Table 12 (CONTINUED)
53
CANCER VACCINES ON THE WORLDWIDE MARKET
53
Melacine
54
Oncovax
55
CANCER VACCINES IN DEVELOPMENT
55
AG-858
55
Allovectin-7
56
Alvac-CEA/B7.1
57
Avicine
58
BEC2
59
Biovaxid
59
BLP25
60
Canvaxin
61
Canvaxin (Continued)
62
CeaVac
63
Cervarix
64
CG7870
64
Collidem
65
Colorectal Cancer Vaccine
65
DCVax-Brain
65
Eladem
66
EP-2101
66
FavId
67
GMK
67
GnRH Pharmaccine
68
GVAX Vaccines
68
GVAX Leukemia Vaccine
68
GVAX Lung Cancer Vaccine
69
GVAX Myeloma Vaccine
70
GVAX Pancreatic Cancer Vaccine
70
GVAX Prostate Cancer Vaccine
71
GVAX Prostate?continued)
72
IGN101
73
Insegia
73
Insegia (Continued)
74
Lung Cancer Vaccines
75
M-Vax
76
MAGE-12: 170-178 Peptide Vaccine
77
MART-1/Melan-A
78
MDX-1379
78
Melacine
79
MUC1 Vaccine
79
Multivalent Antigen Vaccine
79
MVA-HPV-IL2 Vaccine
80
MVA-MUC1-IL2 Vaccine
81
Mylovenge
81
MyVax Personalized Immunotherapy
82
Myvax Personalized Immunotherapy (Continued)
83
Norelin
84
Oncophage
85
Oncophage (Continued)
86
OncoVax
87
Onyvax-P
87
PanVac-VF
88
Patient-specific Vaccines
89
Prostate Cancer Vaccines
90
ProstVac-VF
90
Provenge
90
TA-HPV/TA-CIN
91
TVAX Telomerase Therapeutic Vaccine
91
Table 13 TELOMERASE EXPRESSION RATES BY CANCER TYPE
92
TG4010
93
Theratope
94
TroVax
95
Uvidem
96
HIV/AIDS VACCINES
96
THE HIV INFECTION PROCESS
97
HIV TRANSMISSION
98
CONFUSION REGARDING THE PROPHYLACTIC VERSUS THERAPEUTIC ACTIVITY OF AIDS VACCINES
98
BARRIERS TO DEVELOPING AND TESTING AIDS VACCINES
99
AIDSVAX, THE MOST ADVANCED AIDS VACCINE CANDIDATE BUT WITH DISAPPOINTING NEWS
100
WHAT HAS BEEN LEARNED
101
THE MARKET FOR AIDS VACCINES
102
AIDS VACCINES IN DEVELOPMENT
103
Table 14 SELECTED HIV AND AIDS VACCINES IN PHASE II OR LATER DEVELOPMENT BY DRUG COMPANIES
103
Table 14 (CONTINUED)
104
Results of Early Trials of HIV/AIDS Vaccines
104
Alvac-HIV
105
EP HIV-1090
105
IR103
106
Merck DNA Vaccine
106
Merck/Aventis AIDS Vaccine
107
Remune
107
Remune (Continued)
108
Remune (Continued)
109
Bacteria-based Vaccines
110
INFECTIOUS DISEASE VACCINES (OTHER THAN HIV)
111
NEUROLOGICAL DISEASE VACCINES
111
THE MARKET FOR NEUROLOGICAL DISEASE VACCINES
111
ALZHEIMER'S DISEASE VACCINE
111
MULTIPLE SCLEROSIS VACCINE
112
PARKINSON'S DISEASE VACCINE
113
COMPANY PROFILES
114
ANTIGENICS INC.
114
BUSINESS OVERVIEW
114
FINANCIAL INFORMATION
114
PRODUCTS
114
CORPORATE STRATEGY
115
Corporate Strategy (Continued)
116
APHTON CORPORATION
117
BUSINESS OVERVIEW
117
FINANCIAL INFORMATION
117
PRODUCTS
117
CORPORATE STRATEGY
117
Corporate Strategy (Continued)
118
AVAX TECHNOLOGIES, INC.
119
BUSINESS OVERVIEW
119
FINANCIAL INFORMATION
119
PRODUCTS
120
CORPORATE STRATEGY
121
AVI BIOPHARMA, INC.
122
BUSINESS OVERVIEW
122
FINANCIAL INFORMATION
122
PRODUCTS
123
Table 15 AVI BIOPHARMA'S PRODUCT PIPELINE
123
Table 15 (CONTINUED)
124
CORPORATE STRATEGY
124
BIOMIRA INC.
125
BUSINESS OVERVIEW
125
FINANCIAL INFORMATION
125
PRODUCTS
125
Products (Continued)
126
CORPORATE STRATEGY
127
Corporate Strategy (Continued)
128
BIOVEST INTERNATIONAL, INC.
129
BUSINESS OVERVIEW
129
PRODUCTS
129
CORPORATE STRATEGY
130
CANCERVAX CORP.
130
BUSINESS OVERVIEW
130
FINANCIAL INFORMATION
130
PRODUCTS
131
Table 16 CANCERVAX'S PRODUCT PIPELINE
131
CORPORATE STRATEGY
131
Corporate Strategy (Continued)
132
CELL GENESYS, INC.
133
BUSINESS OVERVIEW
133
FINANCIAL INFORMATION
134
PRODUCTS
134
Table 17 THE CELL GENESYS' PRODUCT PIPELINE
135
CORPORATE STRATEGY
136
CORIXA CORP.
136
BUSINESS OVERVIEW
136
FINANCIAL INFORMATION
137
PRODUCTS
137
Table 18 CORIXA'S PRODUCT PIPELINE
138
CORPORATE STRATEGY
138
DENDREON CORP.
139
BUSINESS OVEVIEW
139
FINANCIAL INFORMATION
139
PRODUCTS
139
Table 19 DENDREON'S PRODUCT PIPELINE
139
Table 19 (CONTINUED)
140
CORPORATE STRATEGY
140
EPIMMUNE, INC.
140
BUSINESS OVERVIEW
140
FINANCIAL INFORMATION
141
PRODUCTS
141
Table 20 EPIMMUNE'S PRODUCT PIPELINE
141
Table 20 (CONTINUED)
142
CORPORATE STRATEGY
142
FAVRILLE, INC.
143
BUSINESS OVERVIEW
143
PRODUCTS
143
CORPORATE STRATEGY
144
GENITOPE CORP.
144
BUSINESS OVERVIEW
144
FINANCIAL INFORMATION
144
PRODUCTS
144
Table 21 GENITOPE'S PRODUCT PIPELINE
145
CORPORATE STRATEGY
145
Corporate Strategy (Continued)
146
GERON CORP.
147
BUSINESS OVERVIEW
147
FINANCIAL INFORMATION
147
PRODUCTS
147
Products (Continued)
148
Table 22 GERON'S PRODUCT PIPELINE
149
CORPORATE STRATEGY
149
IMCLONE SYSTEMS INC.
150
BUSINESS OVERVIEW
150
FINANCIAL INFORMATION
150
LEADING PRODUCT CANDIDATES
150
CORPORATE STRATEGY
150
THE IMMUNE RESPONSE CORP.
151
BUSINESS OVERVIEW
151
FINANCIAL INFORMATION
151
PRODUCTS
151
CORPORATE STRATEGY
151
Corporate Strategy (Continued)
152
INTRACEL HOLDINGS CORP.
153
BUSINESS OVERVIEW
153
PRODUCTS
153
MEDIMMUNE, INC.
153
BUSINESS OVERVIEW
153
FINANCIAL INFORMATION
153
LEADING PRODUCTS
153
Table 23 MEDIMMUNE'S PRODUCT PIPELINE
154
Table 23 (CONTINUED)
155
CORPORATE STRATEGY
155
NABI BIOPHARMACEUTICALS
155
BUSINESS OVERVIEW
155
FINANCIAL INFORMATION
156
PRODUCTS
156
Table 24 NABI BIOPHARMACEUTICALS' PRODUCT PIPELINE
156
CORPORATE STRATEGY
156
NORTHWEST BIOTHERAPEUTICS, INC.
157
BUSINESS OVERVIEW
157
FINANCIAL INFORMATION
157
PRODUCTS
157
Products (Continued)
158
Table 25 NORTHWEST BIOTHERAPEUTICS' PRODUCT PIPELINE
159
CORPORATE STRATEGY
159
Corporate Strategy (Continued)
160
PROGENICS PHARMACEUTICALS, INC.
161
BUSINESS OVERVIEW
161
FINANCIAL INFORMATION
161
PRODUCTS
161
Table 26 PROGENICS' PRODUCT PIPELINE
162
CORPORATE STRATEGY
162
PSMA DEVELOPMENT CO., LLC
162
BUSINESS OVERVIEW
162
FINANCIAL INFORMATION
163
PRODUCTS
163
CORPORATE STRATEGY
163
THERION BIOLOGICS CORP.
164
BUSINESS OVERVIEW
164
PRODUCTS
164
CORPORATE STRATEGY
164
TRANSGENE
164
BUSINESS OVERVIEW
164
FINANCIAL INFORMATION
165
PRODUCTS
165
Table 27 TRANSGENE'S PRODUCT PIPELINE
165
CORPORATE STRATEGY
166
VICAL, INC.
166
BUSINESS OVERVIEW
166
PRODUCTS
167
Table 28 VICAL'S PRODUCT PIPELINE
167
CORPORATE STRATEGY
168
XENOVA GROUP PLC
169
BUSINESS OVERVIEW
169
FINANCIAL INFORMATION
169
PRODUCTS
169
Table 29 XENOVA'S PRODUCT PIPELINE
170
CORPORATE STRATEGY
170
YM BIOSCIENCES INC.
171
BUSINESS OVERVIEW
171
FINANCIAL INFORMATION
171
PRODUCTS
171
Table 30 YM BIOSCIENCES' PRODUCT PIPELINE
172
CORPORATE STRATEGY
172
LIST OF TABLES
Summary Table:
THE WORLDWIDE MARKET FOR THERAPEUTIC VACCINES BY INDICATION, THROUGH 2010 ($ MILLIONS)
XVIII
Table 1 THE WORLDWIDE MARKET FOR ADDICTION VACCINES BY TYPE OF ADDICTION, THROUGH 2010 ($ MILLIONS)
9
Table 2 THE WORLDWIDE MARKET FOR COCAINE ADDICTION VACCINES: THROUGH 2010 ($ MILLIONS)
10
Table 3 THE WORLDWIDE MARKET FOR NICOTINE ADDICTION VACCINES: THROUGH 2010 ($ MILLIONS)
13
Table 4 INCIDENCE, MORTALITY, AND SURVIVAL RATES FOR COMMON CANCERS IN THE U.S., 2003
24
Table 5 CANCER PREVALENCE RATES IN THE U.S., 2003
24
Table 6 ANNUAL INCIDENCE OF, AND DEATH RATES FOR CANCERS FOR WHICH THERAPEUTIC VACCINES ARE IN DEVELOPMENT IN THE U.S., 2003
25
Table 7 TYPES OF VACCINES IN DEVELOPMENT FOR CANCER TREATMENT
42
Table 8 ESTIMATED U.S. MARKET FOR CANCER VACCINES BY INDICATION
44
Table 9 WORLDWIDE MARKET FOR CANCER VACCINES BY TYPE, THROUGH 2010 ($ MILLIONS)
44
Table 10 THE MARKET FOR CANCER VACCINES, BY TECHNOLOGY (AUTOLOGOUS VERSUS ALLOGENEIC), WORLDWIDE, THROUGH 2010 ($ MILLIONS)
45
Table 11 THE WORLDWIDE MARKET FOR CANCER VACCINES, BY INDICATION, THROUGH 2010 ($ MILLIONS)
46
Table 12 CANCER VACCINES IN PHASE II OR LATER TRIALS
48
Table 13 TELOMERASE EXPRESSION RATES BY CANCER TYPE
92
Table 14 SELECTED HIV AND AIDS VACCINES IN PHASE II OR LATER DEVELOPMENT BY DRUG COMPANIES
103
Table 15 AVI BIOPHARMA'S PRODUCT PIPELINE
123
Table 16 CANCERVAX'S PRODUCT PIPELINE
131
Table 17 THE CELL GENESYS' PRODUCT PIPELINE
135
Table 18 CORIXA'S PRODUCT PIPELINE
138
Table 19 DENDREON'S PRODUCT PIPELINE
139
Table 20 EPIMMUNE'S PRODUCT PIPELINE
141
Table 21 GENITOPE'S PRODUCT PIPELINE
145
Table 22 GERON'S PRODUCT PIPELINE
149
Table 23 MEDIMMUNE'S PRODUCT PIPELINE
154
Table 24 NABI BIOPHARMACEUTICALS' PRODUCT PIPELINE
156
Table 25 NORTHWEST BIOTHERAPEUTICS' PRODUCT PIPELINE
159
Table 26 PROGENICS' PRODUCT PIPELINE
162
Table 27 TRANSGENE'S PRODUCT PIPELINE
165
Table 28 VICAL'S PRODUCT PIPELINE
167
Table 29 XENOVA'S PRODUCT PIPELINE
170
Table 30 YM BIOSCIENCES' PRODUCT PIPELINE
172
LIST OF FIGURES
Summary Figure:
THE WORLDWIDE MARKET FOR THERAPEUTIC VACCINES BY INDICATION, 2003-2010
XVIII
Figure 1 PERCENTAGE OF THE MARKET HELD BY AUTOLOGOUS VERSUS ALLOGENEIC CANCER VACCINES, WORLDWIDE, 2005 AND 2010 (%)
46
Figure 2 THERAPEUTIC CANCER VACCINE MARKET SHARE BY COMPANY, 2004 AND 2010 (%)
47